Current approaches to epigenetic therapy for the treatment of mantle cell lymphoma

Advances in Experimental Medicine and Biology

Volumn 779, Issue , 2013, Pages 257-266

  Ghai, Vikas ^a   Sharma, Kamal ^a   Abbi, Kamal K S ^a   Shimko, Sara ^a   Epner, Elliot M ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

5 aza 2 deoxycytidine; AML; B cell lymphoma; Bendamustine; Bortezomib; CD20; CHOP; Cladribine; Cyclin D1; DNA methylation; Epigenetics; HDAC inhibitor; Hypomethylating agent; Immunotherapy; Lenalidomide; Locus control region; Mantle cell lymphoma; MDS; mTOR inhibitors; Oncogenesis; Panobinostat; PET CT; R CHOP; R Hyper CVAD; Rituximab; Romidepsin; Thrombo embolic event; Vorinostat

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AZACITIDINE; BENDAMUSTINE; BORTEZOMIB; CD19 ANTIGEN; CD20 ANTIGEN; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLAVOPIRIDOL; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; IMMUNOTOXIN; KI 67 ANTIGEN; LENALIDOMIDE; MITOXANTRONE; MONOCLONAL ANTIBODY; OFATUMUMAB; PANOBINOSTAT; PREDNISONE; RITUXIMAB; ROMIDEPSIN; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; B CELL LYMPHOMA; BIOACCUMULATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CELL SURFACE; CHRONIC MYELOMONOCYTIC LEUKEMIA; DNA METHYLATION; DNA SEQUENCE; DRUG DOSE REDUCTION; EPIGENETICS; FAILURE FREE SURVIVAL; FATIGUE; FOLLICULAR LYMPHOMA; GENE EXPRESSION REGULATION; GENE SILENCING; HAIRY CELL LEUKEMIA; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; LEUKOPENIA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 84873607850     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-6176-0_11     Document Type: Review

References (37)

1. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6-21.
2. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005;23(17):3971-93.
3. Esteller M. Molecular origins of cancer: Epigenetics in cancer. New Engl J Med. 2008;358(11): 1148-59.
4. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074-80.
5. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, form a complex at replication foci. Nat Genet. 2000;25(3):269-77.
6. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet. 2000;25(3):338-42.
7. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27-36.
8. Lichtenstein M, Keini G, Cedar H, Bergman Y. B-cell-specific demethylation - A novel role for the intronic kappa-chain enhancer sequence. Cell. 1994;76(5):913-23.
9. Madisen L, Krumm A, Hebbes TR, Groudine M. The immunoglobulin heavy chain locus control region increases histone acetylation along linked c-myc genes. Mol Cell Biol. 1998;18(11):6281-92.
10. Herman JG, Baylin SB. Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med. 2003;349(21):2042- 54.
11. Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: Its prevalence and clinical significance. Blood. 2009;113(20):4885-93.
12. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. New Engl J Med. 2004;351(21):2159-69.
13. Wei Y, Agrawal N, Patel J, Edinger A, Osei E, Thut D, et al. Diminished expression of CD19 in B-cell lymphomas. Cytom Part B-Clin Cy. 2005;63B(1):28-35.
14. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209-13.
15. Yoong Y, Kurtin PJ, Allmer C, Geyer S, Habermann TM, Nagorney M, et al. Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma. Leukemia Lymphoma. 2001; 42(6):1235-41.
16. Determann O, Hoster E, Ott G, Bernd HW, Loddenkemper C, Hansmann ML, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: Results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group. Blood. 2008;111(4):2385-7.
17. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20(5):1288-94.
18. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-Term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984-92.
19. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013-23.
20. Epner EM, Unger J, Miller T, Rimza L, Spier C, Leblanc M, et al. A multi center trial of hyperCVAD plus rituxan in patients with newly diagnosed mantle cell lymphoma. Blood. 2007;110(11):121a.
21. Goy A, Kahl B. Mantle cell lymphoma: The promise of new treatment options. Crit Rev Oncol Hemat. 2011;80(1):69-86.
22. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
23. Paulson K, Kumar R, Ahsanuddin A, Seftel MD. Azacytidine as a novel agent in the treatment of acute lymphoblastic leukemia. Leukemia Lymphoma. 2011;52(1):134-6.
24. Blum KA, Liu ZF, Lucas DM, Chen P, Xie ZL, Baiocchi R, et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and Non-Hodgkin lymphoma: Dose-limiting myelosuppression without evidence of DNA hypomethylation. Brit J Haematol. 2010;150(2):189-95.
25. Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: Not just another purine analogue? Expert Opin Inv Drug. 2009;18(8):1169-81.
26. Rummel MJ, Chow KU, Karakas T, Jaager E, Mezger J, Von Grunhagen U, et al. Reduceddose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade Non-Hodgkin's lymphoma. Eur J Cancer. 2002;38(13):1739-46.
27. Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer. 2006;107(7):1542-50.
28. Inwards DJ, Fishkin PAS, Hillman DW, Brown DW, Ansell SM, Kurtin PJ, et al. Long-Term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008;113(1):108-16.
29. Spurgeon SE, Pindyck T, Okada C, Chen YY, Chen ZQ, Mater E, et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leukemia Lymphoma. 2011;52(8):1488-94.
30. Cedar H, Bergman Y. Linking DNA methylation and histone modification: Patterns and paradigms. Nat Rev Genet. 2009;10(5):295-304.
31. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40(6):741-50.
32. Duvic M, Talpur R, Ni X, Zhang CL, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL). Blood. 2007;109(1):31-9.
33. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(9):1198-203.
34. A phase II study of the Histone Deacetylase (HDAC) inhibitor LBH589 (Panobinostat) in patients with relapsed or refractory Non-Hodgkin lymphoma (NCT01261247). www.clinicaltrials.gov.
35. A phase I/II study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in combination with mTOR Inhibitor RAD001 (Everolimus) in patients with relapsed multiple myeloma or lymphoma (NCT00918333). www.clinicaltrials.gov.
36. A Phase II study of depsipeptide, a histone deacetylase inhibitor, in relapsed or refractory mantle cell or diffuse large cell non-Hodgkin's lymphoma (NCT00077194). www.clinicaltrials. gov.
37. Spurgeon S, Chen AI, Okada C, Parekh S, Leshchenko VV, Palmbach G, et al. A Phase I/II Study of vorinostat (SAHA), cladribine (2-CdA), and rituximab shows significant activity in previously untreated mantle cell lymphoma. Blood. 2011;118(21):203.